Aveo Pharmaceuticals (AVEO) 1.34 $AVEO
AVEO-Biodesix Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:00PM CDT
AVEO Pharma entered into an agreement with Biodesix to develop and commercialize ficlatuzumab with VeriStrat.
AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Business Wire - Thu Apr 10, 5:30AM CDT
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix(R) companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat(R), a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 8:39AM CDT
AVEO Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 7% on the day.
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Business Wire - Fri Feb 14, 4:30AM CST
--AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day
PR Newswire - Mon Feb 03, 8:30AM CST
Zacks Equity Research highlights Newport Corporation (Nasdaq:NEWP-Free Report) as the Bull of the Day and Target (NYSE:TGT-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAVEO Pharmaceuticals, Inc. (Nasdaq:AVEO-Free Report), Astellas Pharma, Inc. (OTC:ALPMY-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.
AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer
Business Wire - Thu Jan 30, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient recruitment efforts.
Biotech 2013 by the Numbers: A Blockbuster Year
at The Street - Wed Jan 01, 8:13AM CST
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
AVEO Pharmaceuticals, Inc. (AVEO) Catches Eye: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:44AM CST
AVEO Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by 8% on the day.
AVEO-Biodesix Ink Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 4:00PM CDT
AVEO Pharma entered into an agreement with Biodesix to develop and commercialize ficlatuzumab with VeriStrat.
AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Business Wire - Thu Apr 10, 5:30AM CDT
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix(R) companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat(R), a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). VeriStrat will be used as the selection assay to identify NSCLC patients most likely to benefit from ficlatuzumab.
Technical Pointers on Top Gainers -- Research on Newfield Exploration, Endocyte, Columbia Property Trust, and AVEO Pharma
PR Newswire - Mon Mar 24, 9:09AM CDT
The US markets saw mixed sentiments on Friday, March 21, 2014, with the NASDAQ Composite closing at 4,276.79, down 0.98%, the Dow Jones Industrial Average ending the session at 16,302.77, down 0.17% and the S&P 500 edging 0.29% lower to finish the trading session at 1,866.52. During the session, gains in the Energy, Utilities, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Discretionary, Information Technology, and Health Care sectors. A number of stocks saw large movements, including Newfield Exploration Co. (NYSE: NFX), Endocyte Inc. (NASDAQ: ECYT), Columbia Property Trust Inc. (NYSE: CXP) and AVEO Pharmaceuticals Inc. (NASDAQ: AVEO). Free technical research on NFX, ECYT, CXP and AVEO can be downloaded upon signing up at:
AVEO Pharmaceuticals (AVEO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 8:39AM CDT
AVEO Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 7% on the day.
AVEO Regains AV-203 Rights from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 5:10PM CDT
AVEO Oncology (AVEO) recently announced that it has regained worldwide rights of candidate AV-203 from Biogen Idec (BIIB).
AVEO Oncology regains worldwide rights to AV-203 and seeks partner to accelerate its clinical development
M2 - Fri Mar 21, 5:42AM CDT
Biopharmaceutical company AVEO Oncology (NasdaqGS:AVEO) said on Thursday that it has re -acquired the worldwide rights to AV-203 from Biogen Idec.
AVEO Regains Worldwide Rights to AV-203
Business Wire - Thu Mar 20, 3:30PM CDT
AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
AVEO Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:10AM CDT
AVEO Pharmaceuticals reported a fourth quarter 2013 loss of 32 cents per share.
AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
Business Wire - Thu Mar 13, 2:22PM CDT
--- Focuses internal R&D investment on AV-380 in cachexia -
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Business Wire - Fri Feb 14, 4:30AM CST
--AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Newport, Target, AVEO Pharmaceuticals, Astellas Pharma and Bristol-Myers Squibb highlighted as Zacks Bull and Bear of the Day
PR Newswire - Mon Feb 03, 8:30AM CST
Zacks Equity Research highlights Newport Corporation (Nasdaq:NEWP-Free Report) as the Bull of the Day and Target (NYSE:TGT-Free Report)as the Bear of the Day. In addition, Zacks Equity Research provides analysis onAVEO Pharmaceuticals, Inc. (Nasdaq:AVEO-Free Report), Astellas Pharma, Inc. (OTC:ALPMY-Free Report) and Bristol-Myers Squibb (NYSE:BMY-Free Report).
AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.
AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer
Business Wire - Thu Jan 30, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient recruitment efforts.
Biotech 2013 by the Numbers: A Blockbuster Year
at The Street - Wed Jan 01, 8:13AM CST
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
AVEO Pharmaceuticals, Inc. (AVEO) Catches Eye: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 7:44AM CST
AVEO Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise by 8% on the day.
